Cargando…

Screening for Hepatitis C Virus: How Universal Is Universal?

In March and April of 2020, public health authorities issued major updates to screening recommendations for hepatitis C virus infection. With the rise in cases driven by injection drug use coupled with access to highly effective therapies promising a cure, all adults aged ≥18 years should receive on...

Descripción completa

Detalles Bibliográficos
Autor principal: Jhaveri, Ravi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier Inc. 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7376340/
https://www.ncbi.nlm.nih.gov/pubmed/32712026
http://dx.doi.org/10.1016/j.clinthera.2020.06.012
_version_ 1783562025257926656
author Jhaveri, Ravi
author_facet Jhaveri, Ravi
author_sort Jhaveri, Ravi
collection PubMed
description In March and April of 2020, public health authorities issued major updates to screening recommendations for hepatitis C virus infection. With the rise in cases driven by injection drug use coupled with access to highly effective therapies promising a cure, all adults aged ≥18 years should receive one-time hepatitis C virus antibody screening in any health care setting. Although the recommendation is dubbed “universal,” this commentary reviews the details of the recommendations and discusses the high-risk populations not entirely captured with these changes.
format Online
Article
Text
id pubmed-7376340
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Elsevier Inc.
record_format MEDLINE/PubMed
spelling pubmed-73763402020-07-23 Screening for Hepatitis C Virus: How Universal Is Universal? Jhaveri, Ravi Clin Ther Commentary In March and April of 2020, public health authorities issued major updates to screening recommendations for hepatitis C virus infection. With the rise in cases driven by injection drug use coupled with access to highly effective therapies promising a cure, all adults aged ≥18 years should receive one-time hepatitis C virus antibody screening in any health care setting. Although the recommendation is dubbed “universal,” this commentary reviews the details of the recommendations and discusses the high-risk populations not entirely captured with these changes. Elsevier Inc. 2020-08 2020-07-23 /pmc/articles/PMC7376340/ /pubmed/32712026 http://dx.doi.org/10.1016/j.clinthera.2020.06.012 Text en © 2020 Elsevier Inc. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle Commentary
Jhaveri, Ravi
Screening for Hepatitis C Virus: How Universal Is Universal?
title Screening for Hepatitis C Virus: How Universal Is Universal?
title_full Screening for Hepatitis C Virus: How Universal Is Universal?
title_fullStr Screening for Hepatitis C Virus: How Universal Is Universal?
title_full_unstemmed Screening for Hepatitis C Virus: How Universal Is Universal?
title_short Screening for Hepatitis C Virus: How Universal Is Universal?
title_sort screening for hepatitis c virus: how universal is universal?
topic Commentary
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7376340/
https://www.ncbi.nlm.nih.gov/pubmed/32712026
http://dx.doi.org/10.1016/j.clinthera.2020.06.012
work_keys_str_mv AT jhaveriravi screeningforhepatitiscvirushowuniversalisuniversal